Krebs Biochemicals & Industries Ltd

KREBSBIO

Watchlist

AI Mode

‌

Market Cap

₹ 151 Cr

P/E

—

‌

‌
‌

‌

‌
‌

Investment Checklist

How to read checklist?

Performance

UNDER PERFORMER

Valuation

REASONABLE

Growth

STABLE

Profitability

LOW MARGIN

Technicals

Bullish

Risk

HIGH RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Krebs Biochemicals & Industries Ltd specializes in manufacturing Active Pharmaceutical Ingredients using a unique fermentation process. It is among a few globally employing this method.

The company is engaged in biotechnology, applying its processes in medicine, agriculture, and industry. This includes contract manufacturing for large multinational companies.

Krebs has increased its production capacity from an initial 60 TPA to 150 TPA, demonstrating significant growth since its commercial operations started in 1994.

In 2003-04, the company also branched into renewable energy by commissioning a 2.5 MW co-generation power plant in Vizag.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs

Market Cap

151 Cr

Volatility

High Risk

P/E Ratio

—

Industry P/E

59.2

PEG Ratio

—

P/B Ratio

—

52W High

113.90

52W Low

63.55

Sales CAGR

-14.10%

-10.15%

5.33%

10Y

46.31%

Profit CAGR

-36.54%

—

10Y

—

ROE

TTM

17.42%

19.55%

29.88%

10Y

46.32%

ROCE

TTM

-19.17%

-18.77%

-22.43%

10Y

-20.27%

Technicals

‌

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
PANCHSHEEL	132.95	172 Cr	13.97	1.24	0.61	8.89	11.28	7.20
ASTONEALAB	160.00	168 Cr	31.43	3.00	0.00	8.67	10.26	3.81
AUROLAB	260.00	161 Cr	87.81	3.76	0.00	4.47	7.31	1.55
KIMIABL	32.78	155 Cr	18.88	13.34	0.00	70.62	33.57	8.06
KREBSBIO	70.00	151 Cr	—	0.00	0.00	17.42	-19.17	-16.35
LACTOSE	115.20	145 Cr	32.09	2.32	0.00	7.24	10.49	3.28
SMRUTHIORG	121.70	139 Cr	29.83	1.97	1.23	6.60	10.56	4.69

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Standalone Quarterly Results (in ₹ Crores)

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	11	15	13	12	13	13	11	6.10	5.48	4.17
Expenses	13	16	15	15	15	16	16	12	7.57	6.96
Operating Profit	-2.62	-0.90	-2.09	-3.12	-2.20	-2.71	-4.71	-5.41	-2.09	-2.79
OPM %	-24.76	-6.04	-16.10	-26.07	-17.07	-21.07	-41.06	-88.69	-38.14	-66.91
Other Income	0.04	0.17	0.03	0.21	0.03	0.09	0.25	0.34	0.01	0.01
Interest	1.10	1.13	1.19	1.27	1.32	1.42	1.56	1.61	1.65	1.73
Depreciation	1.65	1.71	1.73	1.67	1.69	1.71	1.72	1.57	1.60	1.62
Profit Before Tax	-5.33	-3.57	-4.98	-5.85	-5.17	-5.76	-7.74	-8.25	-5.32	-6.14
Tax %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.24	0.00	0.00
Net Profit	-5.33	-3.57	-4.98	-5.85	-5.17	-5.76	-7.74	-8.27	-5.32	-6.14
EPS in Rs	-2.47	-1.66	-2.31	-2.72	-2.40	-2.67	-3.59	-3.83	-2.47	-2.85

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	3.53	34	48	33	54	60	52	50	43	36
Expenses	11	41	58	52	71	94	68	59	58	51
Operating Profit	-7.73	-7.50	-9.81	-19	-18	-34	-16	-8.72	-15	-15
OPM %	-218.83	-22.21	-20.55	-55.76	-32.73	-56.94	-30.27	-17.30	-34.70	-41.55
Other Income	-0.33	-1.01	0.44	0.37	0.62	1.16	0.62	0.45	0.71	0.69
Interest	3.49	5.17	6.24	5.93	6.28	5.39	2.97	4.69	5.91	6.24
Depreciation	4.23	4.15	4.40	4.68	5.12	6.30	6.56	6.77	6.69	6.60
Profit Before Tax	-16	-18	-20	-29	-28	-45	-25	-20	-27	-27
Tax %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.06	-0.07
Net Profit	-16	-18	-20	-29	-28	-45	-25	-20	-27	-27
EPS in Rs	-5.41	-8.93	-10.44	-14.18	-13.26	-20.81	-11.30	-9.16	-12.49	-12.74
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	13	14	14	17	18	20	22	22	22	22
Reserves	-0.05	-12	-32	-31	-43	-62	-97	-121	-141	-168
Borrowings	25	43	52	50	66	111	143	183	193	212
Other Liabilities	78	78	92	106	93	91	122	91	104	103
Total Liabilities	116	122	126	142	134	159	190	175	178	169
Fixed Assets	93	102	101	101	105	118	139	147	150	146
CWIP	11	3.50	3.73	3.48	4.19	12	8.38	4.09	2.00	3.09
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	13	16	21	38	24	29	43	24	26	20
Total Assets	116	122	126	142	134	159	190	175	178	169

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	-15	-11	-6.19	3.90	-35	-15	-17	-25	2.30	-7.89
Cash from Investing Activity	-4.00	-4.70	-2.77	-4.32	-10	-23	-23	-13	-7.82	-4.97
Cash from Financing Activity	13	16	9.26	17	29	38	40	37	5.56	13
Net Cash Flow	-6.04	-0.15	0.30	17	-17	0.54	-0.61	-0.01	0.05	0.00

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%
FIIs	0.33%	0.49%	0.49%	0.49%	0.49%	0.49%	0.49%	0.49%	0.49%	0.49%	0.49%	0.49%
DIIs	0.00%	0.00%	0.00%	0.01%	0.00%	0.00%	0.00%	0.01%	0.00%	0.01%	0.01%	0.01%
Public	26.93%	26.76%	26.76%	26.76%	26.76%	26.76%	26.76%	26.76%	26.76%	26.76%	26.76%	26.76%
Total Shareholders	9,293	9,315	9,393	9,030	8,990	8,909	8,848	9,425	9,091	8,798	9,118	8,912

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Nov 26, 2024	Guttikonda rajasekhar	Bulk	Buy	115.85	1.67 Cr	1,43,843	0.66

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Standalone Quarterly Results (in ₹ Crores)

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	11	15	13	12	13	13	11	6.10	5.48	4.17
Expenses	13	16	15	15	15	16	16	12	7.57	6.96
Operating Profit	-2.62	-0.90	-2.09	-3.12	-2.20	-2.71	-4.71	-5.41	-2.09	-2.79
OPM %	-24.76	-6.04	-16.10	-26.07	-17.07	-21.07	-41.06	-88.69	-38.14	-66.91
Other Income	0.04	0.17	0.03	0.21	0.03	0.09	0.25	0.34	0.01	0.01
Interest	1.10	1.13	1.19	1.27	1.32	1.42	1.56	1.61	1.65	1.73
Depreciation	1.65	1.71	1.73	1.67	1.69	1.71	1.72	1.57	1.60	1.62
Profit Before Tax	-5.33	-3.57	-4.98	-5.85	-5.17	-5.76	-7.74	-8.25	-5.32	-6.14
Tax %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.24	0.00	0.00
Net Profit	-5.33	-3.57	-4.98	-5.85	-5.17	-5.76	-7.74	-8.27	-5.32	-6.14
EPS in Rs	-2.47	-1.66	-2.31	-2.72	-2.40	-2.67	-3.59	-3.83	-2.47	-2.85

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	3.53	34	48	33	54	60	52	50	43	36
Expenses	11	41	58	52	71	94	68	59	58	51
Operating Profit	-7.73	-7.50	-9.81	-19	-18	-34	-16	-8.72	-15	-15
OPM %	-218.83	-22.21	-20.55	-55.76	-32.73	-56.94	-30.27	-17.30	-34.70	-41.55
Other Income	-0.33	-1.01	0.44	0.37	0.62	1.16	0.62	0.45	0.71	0.69
Interest	3.49	5.17	6.24	5.93	6.28	5.39	2.97	4.69	5.91	6.24
Depreciation	4.23	4.15	4.40	4.68	5.12	6.30	6.56	6.77	6.69	6.60
Profit Before Tax	-16	-18	-20	-29	-28	-45	-25	-20	-27	-27
Tax %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.06	-0.07
Net Profit	-16	-18	-20	-29	-28	-45	-25	-20	-27	-27
EPS in Rs	-5.41	-8.93	-10.44	-14.18	-13.26	-20.81	-11.30	-9.16	-12.49	-12.74
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	13	14	14	17	18	20	22	22	22	22
Reserves	-0.05	-12	-32	-31	-43	-62	-97	-121	-141	-168
Borrowings	25	43	52	50	66	111	143	183	193	212
Other Liabilities	78	78	92	106	93	91	122	91	104	103
Total Liabilities	116	122	126	142	134	159	190	175	178	169
Fixed Assets	93	102	101	101	105	118	139	147	150	146
CWIP	11	3.50	3.73	3.48	4.19	12	8.38	4.09	2.00	3.09
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	13	16	21	38	24	29	43	24	26	20
Total Assets	116	122	126	142	134	159	190	175	178	169

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	-15	-11	-6.19	3.90	-35	-15	-17	-25	2.30	-7.89
Cash from Investing Activity	-4.00	-4.70	-2.77	-4.32	-10	-23	-23	-13	-7.82	-4.97
Cash from Financing Activity	13	16	9.26	17	29	38	40	37	5.56	13
Net Cash Flow	-6.04	-0.15	0.30	17	-17	0.54	-0.61	-0.01	0.05	0.00

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bullish

Bearish

Neutral

Bullish

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
PANCHSHEEL	132.95	172 Cr	13.97	1.24	0.61	8.89	11.28	7.20
ASTONEALAB	160.00	168 Cr	31.43	3.00	0.00	8.67	10.26	3.81
AUROLAB	260.00	161 Cr	87.81	3.76	0.00	4.47	7.31	1.55
KIMIABL	32.78	155 Cr	18.88	13.34	0.00	70.62	33.57	8.06
KREBSBIO	70.00	151 Cr	—	0.00	0.00	17.42	-19.17	-16.35
LACTOSE	115.20	145 Cr	32.09	2.32	0.00	7.24	10.49	3.28
SMRUTHIORG	121.70	139 Cr	29.83	1.97	1.23	6.60	10.56	4.69

Overview

Detailed Summary

Krebs Biochemicals & Industries Ltd specializes in manufacturing Active Pharmaceutical Ingredients using a unique fermentation process. It is among a few globally employing this method.

The company is engaged in biotechnology, applying its processes in medicine, agriculture, and industry. This includes contract manufacturing for large multinational companies.

Krebs has increased its production capacity from an initial 60 TPA to 150 TPA, demonstrating significant growth since its commercial operations started in 1994.

In 2003-04, the company also branched into renewable energy by commissioning a 2.5 MW co-generation power plant in Vizag.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs

Market Cap

151 Cr

Volatility

High Risk

P/E Ratio

—

Industry P/E

59.2

PEG Ratio

—

P/B Ratio

—

52W High

113.90

52W Low

63.55

Sales CAGR

-14.10%

-10.15%

5.33%

10Y

46.31%

Profit CAGR

-36.54%

—

10Y

—

ROE

TTM

17.42%

19.55%

29.88%

10Y

46.32%

ROCE

TTM

-19.17%

-18.77%

-22.43%

10Y

-20.27%